186 related articles for article (PubMed ID: 33926364)
1. Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review.
Letarouilly JG; Salmon JH; Flipo RM
Expert Opin Drug Saf; 2021 Sep; 20(9):1087-1094. PubMed ID: 33926364
[No Abstract] [Full Text] [Related]
2. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
3. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
5. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review.
Blum MA; Koo D; Doshi JA
Clin Ther; 2011 Jul; 33(7):901-13. PubMed ID: 21715007
[TBL] [Abstract][Full Text] [Related]
6. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
[TBL] [Abstract][Full Text] [Related]
7. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
8. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
9. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.
Tweehuysen L; van den Ende CH; Beeren FM; Been EM; van den Hoogen FH; den Broeder AA
Arthritis Rheumatol; 2017 Feb; 69(2):301-308. PubMed ID: 27696778
[TBL] [Abstract][Full Text] [Related]
10. Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).
Fautrel B; Balsa A; Van Riel P; Casillas M; Capron JP; Cueille C; de la Torre I
Curr Med Res Opin; 2017 Jul; 33(7):1231-1246. PubMed ID: 28358217
[TBL] [Abstract][Full Text] [Related]
11. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
[TBL] [Abstract][Full Text] [Related]
12. Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
Nadkarni A; McMorrow D; Fowler R; Smith D
J Comp Eff Res; 2017 Nov; 6(8):659-669. PubMed ID: 28791873
[TBL] [Abstract][Full Text] [Related]
13. Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al.
van der Maas A; van Herwaarden N; den Broeder AA
Ann Rheum Dis; 2014 Jan; 73(1):e4. PubMed ID: 24078674
[No Abstract] [Full Text] [Related]
14. Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany.
Kostev K; Jacob L
Eur J Clin Pharmacol; 2019 May; 75(5):717-722. PubMed ID: 30666350
[TBL] [Abstract][Full Text] [Related]
15. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
[TBL] [Abstract][Full Text] [Related]
16. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
17. Biologic discontinuation studies: a systematic review of methods.
Yoshida K; Sung YK; Kavanaugh A; Bae SC; Weinblatt ME; Kishimoto M; Matsui K; Tohma S; Solomon DH
Ann Rheum Dis; 2014 Mar; 73(3):595-9. PubMed ID: 23723316
[TBL] [Abstract][Full Text] [Related]
18. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
[TBL] [Abstract][Full Text] [Related]
19. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
Aaltonen KJ; Turunen JH; Sokka T; Puolakka K; Valleala H
Clin Exp Rheumatol; 2016; 34(4):694-7. PubMed ID: 27213997
[TBL] [Abstract][Full Text] [Related]
20. Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review.
López-González R; León L; Loza E; Redondo M; Garcia de Yébenes MJ; Carmona L
Clin Exp Rheumatol; 2015; 33(4):559-69. PubMed ID: 25602291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
